MCID: PRS040
MIFTS: 97

Prostate Cancer malady

Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases categories

Summaries for Prostate Cancer

About this section


MedlinePlus:34 The prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, and being african-american. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation to diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. you may also get a blood test for prostate-specific antigen (psa). these tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. if your results are abnormal, you may need more tests, such as an ultrasound, mri, or biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute

MalaCards based summary: Prostate Cancer, also known as prostate cancer, familial, is related to breast cancer and adenocarcinoma, and has symptoms including autosomal dominant inheritanceand prostate cancer. An important gene associated with Prostate Cancer is AR (androgen receptor), and among its related pathways are Integrated Breast Cancer Pathway and Integrated Pancreatic Cancer Pathway. The drugs aminoglutethimide and chlorotrianisene and the compounds testosterone and serine have been mentioned in the context of this disorder. Affiliated tissues include the prostate, prostate and bone, and related mouse phenotypes are endocrine/exocrine gland and reproductive system.

Disease Ontology:10 A male reproductive organ cancer that is located in the prostate.

CDC:4 Prostate cancer is the most common cancer among American men. Most prostate cancers grow slowly, and don’t cause any health problems in men who have them.

Novus Biologicals:46 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

Wikipedia:65 Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate,... more...

Description from OMIM:47 176807

Aliases & Classifications for Prostate Cancer

About this section
Sources:
47OMIM, 32LifeMap Discovery®, 10Disease Ontology, 11diseasecard, 43NIH Rare Diseases, 22GeneTests, 12DISEASES, 45Novoseek, 49Orphanet, 24GTR, 34MedlinePlus, 4CDC, 62UMLS, 57SNOMED-CT, 35MeSH, 40NCIt, 36MESH via Orphanet, 28ICD10 via Orphanet, 63UMLS via Orphanet, 27ICD10
See all sources

Prostate Cancer, Aliases & Descriptions:

Name: Prostate Cancer 47 32 10 11 12 45 34 4
Prostate Cancer, Familial 47 10 43 62
Malignant Tumor of the Prostate 10 24 62
Hereditary Prostate Cancer 10 43 62
Carcinoma of Prostate 10 22 62
Prostate Carcinoma 10 45 62
Prostate Cancer, Hereditary, 5 47 11
Ngp - New Growth of Prostate 10 62
Prostate Cancer, Hereditary 47 43
Familial Prostate Cancer 43 49
Tumor of the Prostate 10 62
Prostate Cancer, Progression of 47
 
Malignant Neoplasm of Prostate 62
Prostate Cancer, Somatic 47
Prostate Cancer Somatic 47
Prostatic Neoplasms 62
Malignant Neoplasms 62
Prostatic Neoplasm 10
Cancer of Prostate 10
Prostate Cancer 4 47
Prostate Cancer 3 47
Prostate Neoplasm 10
Prostatic Cancer 10


Classifications:



Characteristics (Orphanet epidemiological data):

49
familial prostate cancer:
Prevalence: 1-9/100000 (United States); Age of onset: Adult


External Ids:

OMIM47 176807
Disease Ontology10 DOID:10283, DOID:10286
NCIt40 C3343, C4863
Orphanet49 1331
MESH via Orphanet36 C537243
ICD10 via Orphanet28 C61
UMLS via Orphanet63 C2931456
ICD1027 02, C61

Related Diseases for Prostate Cancer

About this section

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 12 Prostate Cancer, Hereditary, 10
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 14
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 2
Prostate Cancer, Hereditary, 11 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 15 Prostate Cancer 1
Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 310)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer31.2AR, CDH1, BRCA2
2adenocarcinoma31.1PTEN, BRCA2, CHEK2, MSMB, KLF6, MXI1
3leukemia31.1BRCA2, RNASEL, CHEK2, MXI1, CD82
4androgen insensitivity31.1AR, SRD5A2
5gynecomastia31.0BRCA2, SRD5A2, AR
6retinoblastoma30.9BRCA2, CHEK2, KLF6, AR
7melanoma30.7PTEN, BRCA2, CHEK2, MXI1, CD82, CDH1
8colorectal cancer30.6PTEN, KLF6, CD82, CDH1
9glioblastoma30.5PTEN, EPHB2, CHEK2, KLF6, MXI1
10bilateral breast cancer30.4BRCA2, CHEK2
11hepatocellular carcinoma30.1PTEN, BRCA2, SRD5A2, KLF6, CD82, CDH1
12li-fraumeni syndrome30.1PTEN, BRCA2, CHEK2
13lung cancer30.1PTEN, KLF6, CD82, CDH1
14prostatitis12.0
15endotheliitis11.0
16hypoxia10.9
17insulin-like growth factor i10.9
18prostatic hypertrophy10.7
19obesity10.7
20prostate disease10.7
21prostate cancer 110.6
22proctitis10.6
23blindness10.6
24osteoporosis10.5
25hypogonadism10.5
26chronic fatigue syndrome10.5
27disseminated intravascular coagulation10.5
28neuronitis10.5
29neuroectodermal tumor10.5
30adenoma10.4
31alopecia10.4
32urethritis10.4
33impotence10.4
34radiation proctitis10.4
35benign prostate phyllodes tumor10.4
36vaccinia10.4
37herpes simplex10.4
38lynch syndrome10.4
39myeloma10.4
40endodermal sinus tumor10.3
41extragonadal germ cell tumor10.3
42multiple myeloma10.3
43hepatitis10.3
44pituitary apoplexy10.3
45neuroendocrine tumor10.3
46pituitary adenoma10.3
47prostate adenocarcinoma10.3
48prostate cancer, hereditary, 210.3
49prostate cancer, hereditary, x-linked 110.3
50prostate cancer/brain cancer susceptibility, somatic10.3

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to prostate cancer

Symptoms for Prostate Cancer

About this section

Symptoms by clinical synopsis from OMIM:

176807

Clinical features from OMIM:

176807

HPO human phenotypes related to Prostate Cancer:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 prostate cancer HP:0012125

Drugs & Therapeutics for Prostate Cancer

About this section

Genetic Tests for Prostate Cancer

About this section

Genetic tests related to Prostate Cancer:

id Genetic test Affiliating Genes
1 Prostate Cancer22 SRD5A2
2 Malignant Tumor of Prostate24

Anatomical Context for Prostate Cancer

About this section

MalaCards organs/tissues related to Prostate Cancer:

33
Prostate, Bone, Breast, Endothelial, Lymph node, Testes, Skin, T cells, Bone marrow, Lung, Pituitary, Liver, Testis, Colon, Brain, Kidney, Monocytes, Heart, Myeloid, Nk cells, B cells, Adipocyte, Placenta, Spinal cord, Eye, Whole blood, Pancreas, Thyroid, Salivary gland, Ovary, Cervix, Tongue, Pineal

FMA organs/tissues related to Prostate Cancer:

16
The prostate

Animal Models for Prostate Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Prostate Cancer:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537911.7AR, HOXB13, PTEN, ZFHX3, BRCA2, EPHB2
2MP:000538911.7HOXB13, PTEN, ZFHX3, BRCA2, EPHB2, MSMB
3MP:000538411.6RNASEL, BRCA2, PTEN, HOXB13, EPHB2, CHEK2
4MP:001076811.6EPHB2, BRCA2, ZFHX3, PTEN, CHEK2, MSR1
5MP:000200611.5PTEN, ZFHX3, BRCA2, CHEK2, MSMB, MAD1L1
6MP:000538711.3PTEN, BRCA2, RNASEL, CHEK2, MSR1, MSMB
7MP:000539711.1PTEN, BRCA2, RNASEL, CHEK2, MSR1, KLF6
8MP:000538011.0AR, CDH1, KLF6, BRCA2, PTEN, HOXB13
9MP:001077110.7HOXB13, PTEN, BRCA2, KLF6, CDH1, AR

Publications for Prostate Cancer

About this section

Articles related to Prostate Cancer:

(show top 50)    (show all 11015)
idTitleAuthorsYear
1
Re: Effect of Soy Protein Isolate Supplementation on Biochemical Recurrence ofA Prostate Cancer after Radical Prostatectomy: A Randomized Trial. (24331479)
2014
2
Lumican expression, localization and antitumor activity in prostate cancer. (23399832)
2013
3
Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. (23676682)
2013
4
Pre-prostatic tissue removed in robotic assisted lymph node dissection for prostate cancer contains lymph nodes. (24311906)
2013
5
Pre-chemotherapy Abiraterone Acetate. A Proposal of a Treatment Algorithm in Castration Resistant Prostate Cancer. (24342031)
2013
6
No evidence of FGFR3 mutations in prostate cancer. (20957671)
2011
7
PPARI^ disease gene network and identification of therapeutic targets for prostate cancer. (21780947)
2011
8
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. (19820934)
2010
9
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF- kappaB activity in prostate cancer cells. (20068069)
2010
10
CYP17 polymorphisms and prostate cancer outcomes. (20503394)
2010
11
Promising tumor-associated antigens for future prostate cancer therapy. (19536865)
2010
12
Other biomarkers for detecting prostate cancer. (19930175)
2010
13
Investigative clinical study on prostate cancer part III: exploring total PSA and free testosterone distributions and linear correlations in groups and subgroups of operated prostate cancer patients according to the total PSA/FT ratio. (20948186)
2010
14
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. (18762814)
2009
15
Y chromosome haplotypes and prostate cancer in Sweden. (18927315)
2008
16
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. (18703514)
2008
17
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population. (18537123)
2008
18
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. (18628469)
2008
19
P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer]. (18194602)
2007
20
Locally advanced prostate cancer: biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. (17559131)
2007
21
Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. (16698360)
2006
22
Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. (16388505)
2006
23
Characterization of frequently deleted 6q locus in prostate cancer. (17132090)
2006
24
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. (16461912)
2006
25
Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. (16161052)
2006
26
Targeting stathmin in prostate cancer. (16373697)
2005
27
A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. (15727931)
2005
28
Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. (16005185)
2005
29
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. (15266311)
2004
30
Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. (15280008)
2004
31
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. (15390081)
2004
32
Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. (15492805)
2004
33
Vitamin D receptor gene Bsm I polymorphism and the susceptibility to prostate cancer in northern Chinese Han population]. (14574802)
2003
34
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients. (12932112)
2003
35
Metastatic prostate cancer with normal level of serum prostate-specific antigen. (15072491)
2003
36
A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. (12711671)
2003
37
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. (14695191)
2003
38
Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. (11956160)
2002
39
Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human prostate cancer cells. (12269771)
2002
40
The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. (12239635)
2002
41
Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. (11228105)
2001
42
Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. (11746273)
2001
43
A novel human cancer culture model for the study of prostate cancer. (11753687)
2001
44
Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance . (10639187)
2000
45
BRCA1 and BRCA2 have a limited role in familial prostate cancer. (10728701)
2000
46
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. (10475365)
1999
47
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. (10545066)
1999
48
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. (9592622)
1998
49
NGF-beta, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-145, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-beta. (9561567)
1998
50
Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? (9179191)
1997

Variations for Prostate Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Prostate Cancer:

64 (show all 22)
id Symbol AA change Variation ID SNP ID
1CHEK2p.Arg180CysVAR_019103rs77130927
2CHEK2p.Arg181CysVAR_019104rs137853010
3CHEK2p.Arg181HisVAR_019105rs121908701
4CHEK2p.Glu239LysVAR_019106
5CHEK2p.Glu64LysVAR_019107
6CHEK2p.Arg145ProVAR_019108
7CHEK2p.Gly167ArgVAR_019109
8CHEK2p.Arg180HisVAR_019110rs137853009
9CHEK2p.Ile251PheVAR_019111
10CHEK2p.Arg318HisVAR_019112rs143611747
11CHEK2p.Thr323ProVAR_019113
12CHEK2p.Tyr327CysVAR_019114
13CHEK2p.Thr476LysVAR_019115
14EPHB2p.Arg199HisVAR_032853
15EPHB2p.Ala279SerVAR_032854rs35882952
16EPHB2p.Val650AlaVAR_032855rs142173175
17EPHB2p.His679AsnVAR_032856
18EPHB2p.Met883ValVAR_032857
19EPHB2p.Ile909MetVAR_032858
20HOXB13p.Gly84GluVAR_071866
21MXI1p.Glu152AlaVAR_004499
22PTENp.Met134LeuVAR_007469

Clinvar genetic disease variations for Prostate Cancer:

7 (show all 28)
id Gene Variation Type Significance SNP ID Assembly Location
1RNASELNM_021133.3(RNASEL): c.793G> T (p.Glu265Ter)single nucleotide variantPathogenicrs74315364GRCh37Chr 1, 182555149: 182555149
2RNASELNM_021133.3(RNASEL): c.3G> A (p.Met1Ile)single nucleotide variantPathogenicrs74315365GRCh37Chr 1, 182555939: 182555939
3EHBP1NM_001142615.2(EHBP1): c.1185+30064G> Asingle nucleotide variantPathogenicrs721048GRCh37Chr 2, 63131731: 63131731
4MSMBNM_002443.3(MSMB): c.-89T=single nucleotide variantPathogenicrs10993994GRCh37Chr 10, 51549496: 51549496
5MSR1NM_138715.2(MSR1): c.877C> T (p.Arg293Ter)single nucleotide variantPathogenicrs41341748GRCh37Chr 8, 16012594: 16012594
6MSR1NM_138715.2(MSR1): c.520G> T (p.Asp174Tyr)single nucleotide variantPathogenicrs72552387GRCh37Chr 8, 16026077: 16026077
7ZFHX3ZFHX3, 24-BP DEL, NT10814deletionPathogenic
8ELAC2NM_018127.6(ELAC2): c.650C> T (p.Ser217Leu)single nucleotide variantPathogenicrs4792311GRCh37Chr 17, 12915009: 12915009
9ELAC2NM_018127.6(ELAC2): c.1621G> A (p.Ala541Thr)single nucleotide variantPathogenicrs5030739GRCh37Chr 17, 12899902: 12899902
10ELAC2NM_018127.6(ELAC2): c.1641dupG (p.His548Alafs)duplicationPathogenicrs387906327GRCh37Chr 17, 12899881: 12899882
11ELAC2NM_018127.6(ELAC2): c.2342G> A (p.Arg781His)single nucleotide variantPathogenicrs119484086GRCh37Chr 17, 12896274: 12896274
12ELAC2NM_018127.6(ELAC2): c.1865A> T (p.Glu622Val)single nucleotide variantPathogenicrs119484087GRCh37Chr 17, 12898323: 12898323
13EPHB2NM_004442.6(EPHB2): c.2167C> T (p.Gln723Ter)single nucleotide variantPathogenicrs121912582GRCh37Chr 1, 23234473: 23234473
14EPHB2NM_004442.6(EPHB2): c.835G> T (p.Ala279Ser)single nucleotide variantPathogenicrs35882952GRCh37Chr 1, 23189553: 23189553
15EPHB2NM_004442.6(EPHB2): c.2035G> A (p.Asp679Asn)single nucleotide variantPathogenicrs28936395GRCh37Chr 1, 23233346: 23233346
16EPHB2NM_004442.6(EPHB2): c.*187A> Tsingle nucleotide variantrisk factorrs76826147GRCh37Chr 1, 23240250: 23240250
17BRCA2BRCA2, 1-BP DEL, 6051AdeletionPathogenic
18BRCA2BRCA2, 1-BP INS, 2558AinsertionPathogenic
19MXI1MXI1, 1-BP DEL, A, CODON 140 OR 141deletionPathogenic
20MXI1NM_130439.3(MXI1): c.552+2T> Csingle nucleotide variantPathogenicrs387906417GRCh37Chr 10, 112039054: 112039054
21MXI1NM_130439.3(MXI1): c.656A> C (p.Glu219Ala)single nucleotide variantPathogenicrs137852603GRCh37Chr 10, 112039775: 112039775
22ARNM_000044.3(AR): c.1943G> A (p.Ser648Asn)single nucleotide variantPathogenicrs137852584GRCh37Chr X, 66931301: 66931301
23ARNM_000044.3(AR): c.2191G> A (p.Val731Met)single nucleotide variantPathogenicrs137852571GRCh37Chr X, 66937337: 66937337
24ARNM_000044.3(AR): c.2632A> G (p.Thr878Ala)single nucleotide variantPathogenicrs137852578GRCh37Chr X, 66943552: 66943552
25ARNM_000044.3(AR): c.2633C> G (p.Thr878Ser)single nucleotide variantPathogenicrs137852580GRCh37Chr X, 66943553: 66943553
26ARNM_000044.3(AR): c.2623C> T (p.His875Tyr)single nucleotide variantPathogenicrs137852581GRCh37Chr X, 66943543: 66943543
27ARNM_000044.3(AR): c.2708A> G (p.Gln903Arg)single nucleotide variantPathogenicrs137852582GRCh37Chr X, 66943628: 66943628
28ARNM_000044.3(AR): c.2164G> A (p.Ala722Thr)single nucleotide variantPathogenicrs137852583GRCh37Chr X, 66931522: 66931522

Cosmic variations for Prostate Cancer:

8
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1763PIK3CAskin,back,carcinoma,basal cell carcinoma1

Expression for genes affiliated with Prostate Cancer

About this section

Search GEO for disease gene expression data for Prostate Cancer.

Pathways for genes affiliated with Prostate Cancer

About this section

Pathways related to Prostate Cancer according to GeneCards/GeneDecks:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
111.0PTEN, BRCA2, CHEK2, CDH1, AR
211.0PTEN, BRCA2, CHEK2, CD82, AR
3
Show member pathways
Signaling Pathways in Glioblastoma38
11.0PTEN, BRCA2, SRD5A2, CDH1, AR
410.9PTEN, BRCA2, CDH1, AR
5
Show member pathways
Prostate Cancer38
Integrated Cancer pathway38
Steroid Biosynthesis38
10.8PTEN, AR, CHEK2
6
Show member pathways
Cell cycle38
10.8MAD1L1, CDH1, CHEK2
7
Show member pathways
Translation Non genomic rapid action of Androgen Receptor60
10.8PTEN, SRD5A2, AR
8
Show member pathways
DNA damage response38
10.8PTEN, CHEK2, CD82

Compounds for genes affiliated with Prostate Cancer

About this section

Compounds related to Prostate Cancer according to GeneCards/GeneDecks:

(show all 39)
idCompoundScoreTop Affiliating Genes
1testosterone45 61 26 1314.7CDH1, AR, MSMB, MSR1, RNASEL, BRCA2
2serine4511.6CHEK2, EPHB2, PTEN, MAD1L1, KLF6, CDH1
3tyrosine4511.5EPHB2, MSMB, MSR1, CHEK2, CD82, CDH1
4arginine4511.4CDH1, AR, SRD5A2, EPHB2, PTEN, RNASEL
5phosphatidylinositol4511.4CDS1, PTEN, BRCA2, EPHB2, CHEK2, CDH1
6estrogen4511.4PTEN, SRD5A2, KLF6, CDH1, AR, BRCA2
7retinoic acid45 2612.4AR, CHEK2, BRCA2, CDH1, EPHB2, PTEN
8etoposide45 51 61 1314.4CDH1, AR, CHEK2, BRCA2, PTEN
9genistein45 30 61 3 26 1316.4AR, CDH1, BRCA2, PTEN, CHEK2
10paraffin4511.4CDH1, AR, PTEN, BRCA2, CD82
11progesterone45 30 61 26 1315.3SRD5A2, PTEN, CDH1, AR, BRCA2
12steroid4511.3MSMB, BRCA2, AR, PTEN, SRD5A2
13indole-3-carbinol4511.3AR, CDH1, BRCA2, PTEN
14adenine45 26 1313.3AR, CDH1, RNASEL, SRD5A2
15n acetylcysteine4511.2AR, CHEK2, MSR1, CDH1
16tamoxifen45 51 30 1314.2PTEN, AR, CDH1, BRCA2
17vitamin d4511.2PTEN, SRD5A2, AR, CDH1
18paclitaxel45 51 1313.2BRCA2, CDH1, MAD1L1, PTEN
19rapamycin4511.2CDH1, CHEK2, PTEN, AR
20doxorubicin45 51 1313.2CDH1, PTEN, AR, CHEK2
21estradiol45 26 1313.2BRCA2, PTEN, AR, SRD5A2
22glutamine4511.1CDH1, AR, BRCA2, SRD5A2
23nocodazole45 1312.1CHEK2, CDH1, MAD1L1
24adriamycin4511.1CDH1, CHEK2, BRCA2
25troglitazone45 30 61 1314.1CDH1, AR, PTEN
26dutasteride45 1312.0AR, SRD5A2
27cisplatin45 51 61 1314.0BRCA2, PTEN, CDH1, CHEK2
28docetaxel45 51 61 1314.0CDH1, BRCA2, AR
29leucine4511.0CDH1, MXI1, SRD5A2, PTEN
30dihydrotestosterone45 30 26 1314.0AR, SRD5A2, CDH1
31mg 13245 6112.0CDH1, PTEN, AR
32sodium bisulfite4510.9CDH1, AR
33finasteride45 61 26 1313.9AR, SRD5A2
345-aza-2deoxycytidine4510.9PTEN, CDH1, AR
35adenylate4510.9RNASEL, KLF6, CDH1, AR
36calcitriol45 61 26 1313.8PTEN, CDH1, AR
37danazol45 26 1312.7AR, CDH1
38o6-methylguanine4510.6BRCA2, CDH1
39cycloheximide4510.6AR, RNASEL, PTEN, BRCA2

GO Terms for genes affiliated with Prostate Cancer

About this section

Cellular components related to Prostate Cancer according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:000563411.4HOXB13, PTEN, ZFHX3, BRCA2, ELAC2, MSMB
2Schmidt-Lanterman incisureGO:004322010.4PTEN, CDH1

Biological processes related to Prostate Cancer according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription, DNA-templatedGO:004589311.0CHEK2, AR, CDH1, KLF6, BRCA2
2response to gamma radiationGO:001033210.7BRCA2, CHEK2
3dendritic spine morphogenesisGO:006099710.6EPHB2, PTEN
4negative regulation of axonogenesisGO:005077110.4EPHB2, PTEN

Products for genes affiliated with Prostate Cancer

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Prostate Cancer

About this section
4CDC
15ExPASy
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
52PubMed
53QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet